Coronavirus updates: Over 7,000 Americans died in past week

The increase comes less than two weeks after Halloween.

A pandemic of the novel coronavirus has now killed more than 1.3 million people worldwide.

Over 53.2 million people across the globe have been diagnosed with COVID-19, the disease caused by the new respiratory virus, according to data compiled by the Center for Systems Science and Engineering at Johns Hopkins University. The actual numbers are believed to be much higher due to testing shortages, many unreported cases and suspicions that some national governments are hiding or downplaying the scope of their outbreaks. The criteria for diagnosis -- through clinical means or a lab test -- has also varied from country to country.

Nearly 200 vaccine candidates for COVID-19 are being tracked by the World Health Organization, at least 10 of which are in crucial phase three studies. Of those 10 potential vaccines in late-stage trials, there are currently five that will be available in the United States if approved.


0

Ethiopia's case count tops 100,000 amid fears of civil war

Ethiopia has confirmed more than 100,000 COVID-19 cases, becoming one of just a handful of countries across Africa that have surpassed the grim milestone.

Other African countries with over 100,000 confirmed cases as of Wednesday are Egypt with 109,000, Morocco with 265,000 and South Africa with 740,000. Meanwhile, the 54-nation African continent is approaching 2 million confirmed cases, according to the latest data from the Africa Centers for Disease Control and Prevention.

The development comes as Ethiopia, one of Africa's most populous countries, appears to be on the brink of civil war amid increasingly deadly skirmishes in its northern Tigray region between federal forces and Tigray's ones.

The United Nations and other groups have warned of a brewing humanitarian crisis that could affect up to 9 million people.


England to give university students 7-day window to travel home for Christmas

University students in England will be given a seven-day window next month to travel home before Christmas, with school campuses providing mass testing before they leave, according to new guidance published Wednesday by the U.K. government.

After a second nationwide lockdown ends on Dec. 2, students will be allowed to travel home on staggered departure dates set by universities from Dec. 3 to Dec. 9.

"The student travel window will mean students can travel having just completed the four-week period of national restrictions, reducing the risk of transmission to family and friends at home," the U.K. government said in a press release announcing the new guidance.

The government is urging universities to transition to remote learning by Dec. 9 so students can continue their education while also having the option to return home to study from there. The government said it will also work closely with universities to establish mass COVID-19 testing capacity.

"Tests will be offered to as many students as possible before they travel home for Christmas, with universities in areas of high prevalence prioritised," the government said. "If a student tests positive before their departure they will need to remain in self-isolation for the required period of 10 days. Moving all learning online by 9 December gives enough time for students to complete the isolation period and return home for Christmas."

English students at universities in Scotland, Wales or Northern Ireland are instructed to follow the guidance relevant to where they are living before returning home.

The U.K. government's universities minister, Michelle Donelan, acknowledged that the upcoming holidays "will feel different this year" due to the unprecedented situation.

"We have worked really hard to find a way to do this for students, while limiting the risk of transmission," Donelan said in a statement Wednesday. "Now it is vital they follow these measures to protect their families and communities, and for universities to make sure students have all the wellbeing support they need, especially those who stay on campus over the break."


Texas becomes 1st US state to surpass 1 million cases

Texas has confirmed its one-millionth case of COVID-19, becoming the first U.S. state to do so.

The Lone Star state confirmed 12,337 new cases in the past day, bringing its cumulative total to 1,010,364 confirmed cases as of early Wednesday. The state also registered an additional 114 fatalities from COVID-19, bringing its death toll to 19,337, according to a real-time count kept by Johns Hopkins University.

Texas's seven-day moving average of daily positive COVID-19 tests stands at 10%. Current hot spots within the southwestern state include the areas of Austin, Dallas, El Paso, Houston and San Antonio, according to Johns Hopkins data.

Meanwhile, California is on track to become the second U.S. state to surpass 1 million confirmed cases. The Golden State confirmed 8,135 new cases in the past day, bringing its cumulative total to 989,432 confirmed cases as of early Wednesday, according to Johns Hopkins data.


Europe clinches deal to buy up to 300M doses of Pfizer/BioNTech vaccine

Pfizer and BioNTech announced Wednesday that they have reached an agreement to supply up to 300 million doses of their experimental COVID-19 vaccine to Europe.

The agreement with the European Commission provides a supply of 200 million doses and an option to request an additional 100 million doses, according to a joint press release from Pfizer and BioNTech.

Doses allocated for European Union member states will be produced in BioNTech's manufacturing sites in Germany as well as at Pfizer's site in Belgium. If the vaccine candidate receives authorization from the European Medicines Agency, then doses will be ordered by the EU member states who have elected to receive the vaccine as part of the agreement.

Deliveries are anticipated to start by the end of 2020, subject to clinical success and regulatory approval, according to the press release.

"Today’s finalized supply agreement with the European Commission represents the largest initial order of vaccine doses for Pfizer and BioNTech to date and a major step toward our shared goal of making a COVID-19 vaccine available to vulnerable populations," Pfizer chairman and CEO Albert Bourla said in a statement Wednesday.

Last month, the European Medicines Agency began a rolling review of data on the efficacy and safety of the vaccine candidate to determine whether the drug should be authorized for use.

Pfizer, a New York-based pharmaceutical giant, and BioNTech, a German biotechnology company, announced Monday that the experimental vaccine appears to be at least 90% effective in an early analysis. The European Medicines Agency said in a statement Monday that it "has not yet had a chance to formally assess these efficacy data."